Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amy Volkmann

Physician Assistant Suffolk, VA Physician Assistant

NPI 1295048643 CMS profile 10745318

3907 Bridge Rd Ste 200, Suffolk, VA 23435

Open in the dashboard

General payments

$12,834

610 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy Volkmann of Suffolk, VA is reported in the CMS Open Payments database as having received $12,834 across 610 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,974 131
2024 General $3,286 147
2023 General $2,572 118
2022 General $2,020 103
2021 General $1,983 111

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Volkmann
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Amy Volkmann were reported at $2,974. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Amy Volkmann Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,983 $132 $37–$438 $132
2022 $2,020 $155 $48–$522 $149
2023 $2,572 $167 $52–$557 $160
2024 $3,286 $178 $55–$600 $164
2025 $2,974 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,727 129 payments
  2. Regeneron Healthcare Solutions, Inc. $1,263 56 payments
  3. Janssen Biotech, Inc. $1,239 62 payments
  4. UCB, Inc. $1,034 60 payments
  5. Amgen Inc. $981 40 payments
  6. Genzyme Corporation $945 50 payments
  7. Novartis Pharmaceuticals Corporation $901 37 payments
  8. LEO Pharma Inc. $663 30 payments
  9. Pfizer Inc. $513 30 payments
  10. Sun Pharmaceutical Industries Inc. $470 23 payments
  11. Other $2,100 93 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,274 602 payments
  2. Education $561 8 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,291 69 payments
  2. RINVOQ $1,165 51 payments
  3. TREMFYA $1,156 56 payments
  4. Otezla $981 40 payments
  5. SKYRIZI Immunology $969 43 payments
  6. DUPIXENT Inflammation And Immunology $959 35 payments
  7. Bimzelx $624 27 payments
  8. ADBRY $570 24 payments
  9. COSENTYX $534 26 payments
  10. SKYRIZI Immunology $437 21 payments
  11. Other $6,176 333 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

942

Median for Physician Assistant: 241

Drug cost

$670,059

Median for Physician Assistant: $4,110

Branded share of claims

19.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 14 $193,890
Dupixent Pen Dupilumab Brand 40 $161,978
Cosentyx Unoready Pen Secukinumab Brand 11 $106,393
Dupixent Syringe Dupilumab Brand 27 $102,859
Otezla Apremilast Brand 13 $63,909
Oracea Doxycycline Monohydrate Brand 12 $10,156
Fluorouracil Generic 80 $5,764
Clobetasol Propionate Generic 120 $5,466
Tacrolimus Generic 40 $5,203
Metronidazole Generic 41 $2,561

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$169,751

Of which drugs: $19,093

Medicare patients

978

Average age 75

Services billed

13,684

627 women, 351 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 48%
Diabetes 26%
Ischemic heart disease 21%
Osteoporosis 18%
Atrial fibrillation 16%
Chronic kidney disease 16%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 25 9,400 $12,250
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 15 23 $6,806
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 26 50 $38

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $531
$531 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $281
  • GENZYME CORPORATION $206
$487 67 —
SKYRIZI
  • AbbVie, Inc. $392
$392 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $326
$326 11 —
Otezla
  • Amgen Inc. $286
$286 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

610 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record